COVID-19 pneumonia and its progression to respiratory failure appear to be driven by an immune hyperreaction in which IL-6 and ET-1 play an important role. Vitamin C can reduce these (and other) inflammatory mediators in various inflammatory condi- tions, and is clinically beneficial in (non-COVID-19) hypertensive and/or diabetic obese adult patients. Considering the weight of the evidence and because vitamin C is cheap and safe, an oral low dose (1!2 g/d) may be useful prophylactically, and in cases of severe COVID-19, a (very) high-dose regimen may be beneficial. Ongoing clinical trials are expected to provide more definitive evidence.
Read the full study hereΚάντε subscribe στο μηνιαίο μας newsletter